You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Response to PD1 inhibition in conventional chondrosarcoma
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, September 2018
|
| DOI | 10.1186/s40425-018-0413-z |
| Pubmed ID | |
| Authors |
Michael J. Wagner, Robert W. Ricciotti, Jose Mantilla, Elizabeth T. Loggers, Seth M. Pollack, Lee D. Cranmer |
| Abstract |
Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy. We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response. Conventional chondrosarcoma may be sensitive to checkpoint inhibitors. Further, this case demonstrates clearly the phenomenon of pseudo-progression in this disease, a factor that must be considered in the design of clinical trials and clinical care. This case supports additional study of immunomodulatory agents in this deadly disease. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 67% |
| India | 1 | 11% |
| Italy | 1 | 11% |
| Unknown | 1 | 11% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 44% |
| Science communicators (journalists, bloggers, editors) | 2 | 22% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 24% |
| Researcher | 3 | 18% |
| Student > Doctoral Student | 2 | 12% |
| Student > Ph. D. Student | 2 | 12% |
| Professor | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 3 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 41% |
| Biochemistry, Genetics and Molecular Biology | 3 | 18% |
| Veterinary Science and Veterinary Medicine | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Engineering | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 4 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2018.
All research outputs
#6,600,501
of 25,461,852 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,584
of 3,436 outputs
Outputs of similar age
#108,337
of 351,148 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#25
of 36 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,436 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,148 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.